AstraZeneca’s CALQUENCE demonstrates enhanced efficacy in mantle cell lymphoma trial
AstraZeneca has announced significant outcomes from the ECHO Phase III trial, highlighting the effectiveness of its drug CALQUENCE (acalabrutinib) when combined with bendamustine and rituximab ... Read More